Showing results (2621-2630 of 6,517) with videos related to

Sort By:
Pageof 652
Cancer Immunology, Immunotherapy : CII|September 13, 2025
High baseline PD-1+ CD8 T Cells and TIGIT+ CD8 T Cells in circulation associated with response to PD-1 blockade in patients with non-small cell lung cancerNikita Dutta, Johanna Svensson, George-Alehandro Saad, et al.
Cancer Immunology, Immunotherapy : CII|September 13, 2025
Tertiary lymphoid structures gene signature predicts response to immunotherapy plus chemotherapy in advanced non-small cell lung cancerWei Du, Bijing Xiao, Xuan Yang, et al.
Cancer Immunology, Immunotherapy : CII|October 24, 2025
Bispecific antibodies (PD-1/CTLA-4) vs. PD-1 inhibitors with platinum-based chemotherapy±bevacizumab as first-line therapy for persistent, recurrent, or metastatic cervical cancer: a retrospective matched cohort studyXin Wang, Yaqin Wu, Jian Huang, et al.
Cancer Immunology, Immunotherapy : CII|July 24, 2025
Preclinical evaluation of a CCL19 immune-potentiated DNA cancer vaccineSøren Vester Kofoed, Marina Barrio-Calvo, Michail Angelos Pavlidis, et al.
Cancer Immunology, Immunotherapy : CII|March 27, 2025
RNF2 induces myeloid-derived suppressor cells chemotaxis and promotes hepatocellular carcinoma progression through the TRAF2-NF-κB signaling axisManman Liang, Jianghua Yang, Aiping Zhang, et al.
Cancer Immunology, Immunotherapy : CII|March 24, 2025
Prognostic significance of cytotoxic-T-lymphocytes to immunosuppressive lymphocytes ratio (CIL) in laryngeal squamous cell carcinomaDuo Zhang, Yu Heng, Qiu-Yan Jin, et al.
Cancer Immunology, Immunotherapy : CII|July 27, 2014
Foxp3 expression in T regulatory cells and other cell lineagesChristel Devaud, Phillip K Darcy, Michael H Kershaw
Cancer Immunology, Immunotherapy : CII|August 1, 2014
Functional autoantibodies against SSX-2 and NY-ESO-1 in multiple myeloma patients after allogeneic stem cell transplantationTim Luetkens, Sebastian Kobold, Yanran Cao, et al.
Cancer Immunology, Immunotherapy : CII|December 3, 2013
The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancerNicola E Annels, Victoria E Shaw, Rachel F Gabitass, et al.
Cancer Immunology, Immunotherapy : CII|December 4, 2013
Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancerChristian J Maine, Nor Haslinda Abdul Aziz, Jayanta Chatterjee, et al.
Pageof 652